checkAd
    Startseite > Aktien > Roche Holding > Nachrichten
    Roche Holding Aktie
    32,77
     
    USD
    -0,12 %
    -0,04 USD
    Letzter Kurs 02:10:00 Nasdaq OTC
    ISIN: US7711951043 · WKN: 891106 · SYM: RHHBY · Schweiz

    Neueste Nachrichten

    Genentech Reports Positive Phase Ib Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People With Obesity
    16.05.24 · Business Wire (engl.) · Roche Holding
    [Ad hoc announcement pursuant to Art. 53 LR] Roche reports positive Phase I results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity
    16.05.24 · globenewswire · Roche Holding
    Roche announces FDA approval of one of the first HPV self-collection solutions in the U.S., expanding access and screening options to help eliminate cervical cancer
    15.05.24 · globenewswire · Roche Holding
    [Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19
    24.04.24 · globenewswire · Roche Holding
    [Ad hoc-Mitteilung gemäss Art. 53 KR] Verkäufe der Roche-Gruppe steigen im ersten Quartal um 2% (CER); beide Divisionen Pharma und Diagnostics wachsen im hohen einstelligen Bereich ohne COVID-19-Produkte
    24.04.24 · globenewswire · Roche Holding
    FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
    19.04.24 · globenewswire · Roche Holding
    FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer
    18.04.24 · Business Wire (engl.) · Roche Holding
    Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS
    17.04.24 · Business Wire (engl.) · Roche Holding
    Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS
    17.04.24 · globenewswire · Roche Holding
    Genentech’s Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study
    15.04.24 · Business Wire (engl.) · Roche Holding
    [Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study
    15.04.24 · globenewswire · Roche Holding
    Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis
    11.04.24 · globenewswire · Roche Holding